Furthermore, characteristic examples of novel approaches are CAR T cells, which target specific antigens like glypican-3 (GPC3) T cell receptor (TCR)-based therapies, therapeutic vaccines aiming to enhance tumor-specific immune responses, HLA peptidomics and neoantigen identification, toll-like receptor, cGAS–STING RIGI or MDA5, and inflammasome agonists [131,132,133,134,135,136,137,138,139,140]. This evidence concerns the gene STING1 and neoplasm.